Prognostic factors for multiple myeloma in the era of novel agents
Ann Oncol
.
2008 Sep:19 Suppl 7:vii117-20.
doi: 10.1093/annonc/mdn437.
Authors
J Bladé
1
,
L Rosiñol
,
M T Cibeira
Affiliation
1
Institut of Hematology and Oncology, Department of Hematology, IDIBAPS, Hospital Clinic, Barcelona, Spain.
PMID:
18790932
DOI:
10.1093/annonc/mdn437
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Review
MeSH terms
Humans
Multiple Myeloma / diagnosis*
Multiple Myeloma / drug therapy
Multiple Myeloma / genetics
Multiple Myeloma / therapy*
Neoplasm Staging
Prognosis